Irritable Bowel Syndrome (IBS) Treatment Market Grows Amidst Escalating Prevalence Driver: A Major Catalyst in the Evolution of the Irritable Bowel Syndrome (IBS) Treatment Market in 2025

What combination of drivers is leading to accelerated growth in the irritable bowel syndrome (ibs) treatment market?
The increase in irritable bowel syndrome (IBS) commonness is anticipated to spur the advancement of the IBS treatment market in the future. IBS is a persistent condition that impacts the large intestine. This uptick in IBS occurrence can be attributed to unhealthy lifestyles, poor dietary practices, exposure to pollutants, and elevated stress levels. The role of IBS treatment is to decrease the intensity and regularity of IBS manifestations, enhance life quality, and assist individuals in better managing their health status. As per data from the International Foundation for Gastrointestinal Disorders (IFFGD), an American non-profit educational and research institution, about 5-10% of the global population is projected to have IBS in 2023, and between 25 and 45 million individuals in the United States are likely to be affected by IBS. Consequently, the IBS treatment market growth is propelled by the increasing prevalence of irritable bowel syndrome (IBS).

Get Your Irritable Bowel Syndrome (IBS) Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

What is the projected compound annual growth rate (CAGR) of the irritable bowel syndrome (ibs) treatment market from 2025 to 2034, and what factors influence it?
The market for treating irritable bowel syndrome (IBS) has witnessed rapid expansion over the recent years. It is projected to increase from $2.79 billion in 2024 to $3.07 billion in 2025, representing a compound annual growth rate (CAGR) of 10.2%. The rise experienced during the historic period can be traced back to the factors such as higher incidence rates of IBS, an enhanced level of patient awareness, lifestyle and stress-related factors, along with patient support groups and advocacy, as well as beneficial healthcare reimbursement policies.

The market size for treating irritable bowel syndrome (IBS) is projected to witness significant expansion in the coming years. It is forecasted to reach $4.93 billion by 2029, with a compound annual growth rate (CAGR) of 12.5%. This growth during the forecast period can be credited to factors such as patient-focused healthcare models, microbial treatments, the use of blockchain in healthcare, patient-reported outcomes (pros), quickened regulatory programs, and the interchangeable use of health data. The major trends expected during this period include the incorporation of digital health solutions, advancements in diagnostic technologies, increased funding for research and development, strategic collaborations and partnerships, and the rise of non-pharmaceutical therapies.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp

How are the latest trends influencing the growth of the irritable bowel syndrome (ibs) treatment market?
The irritable bowel syndrome (IBS) market is witnessing a rising trend in product innovation. Leading market players in the IBS sector are tirelessly working towards developing unique, cutting-edge products to solidify their foothold in the market. For example, Ardelyx, a biotech firm based in the US, unveiled IBSRELA in April 2022. This first-of-its-kind treatment for IBS-C in adults is the only available NHE3 inhibitor for managing adult irritable bowel syndrome with constipation (IBS-C). The first Ardelyx drug to secure FDA approval, IBSRELA introduces a fresh, revolutionary mechanism for IBS-C treatment that hasn't been seen for nearly a decade. It significantly expands treatment options for constipation, bloating, and abdominal pain, common symptoms of this debilitating condition.

What are the major segments of the irritable bowel syndrome (ibs) treatment market and their role in driving growth?
The irritable bowel syndrome (IBS) treatment market covered in this report is segmented -

1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings

Subsegments:
1) By Lubiprostone: Chronic Idiopathic Constipation Treatment, Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
2) By Linaclotide: IBS-C Treatment, Chronic Idiopathic Constipation Treatment
3) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment
4) By Rifaximin: IBS-D Treatment, Small Intestinal Bacterial Overgrowth (SIBO) Treatment
5) By Alosetron: Severe IBS-D Treatment for Women
6) By Other Drugs: Prucalopride, Tenapanor, Plecanatide

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11978

Which regions are key players in the growth of the irritable bowel syndrome (ibs) treatment market?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (IBS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the irritable bowel syndrome (ibs) treatment market?
Major companies operating in the irritable bowel syndrome (IBS) treatment market include Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp

What Is Covered In The Irritable Bowel Syndrome (IBS) Treatment Global Market Report?

• Market Size Forecast: Examine the irritable bowel syndrome (ibs) treatment market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the irritable bowel syndrome (ibs) treatment market for a structured understanding.
• Key Players Overview: Analyze major players in the irritable bowel syndrome (ibs) treatment market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the irritable bowel syndrome (ibs) treatment market.
• Segment Contributions: Evaluate how different segments drive overall growth in the irritable bowel syndrome (ibs) treatment market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the irritable bowel syndrome (ibs) treatment market.
• Industry Challenges: Identify potential risks and obstacles affecting the irritable bowel syndrome (ibs) treatment market.
• Competitive Landscape: Review strategic developments in the irritable bowel syndrome (ibs) treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.